The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jong Hyun, Choi, Juwhan, Chung, Sang Mi, Oh, Jee Youn, Lee, Young Seok, Min, Kyung Hoon, Hur, Gyu Young, Shim, Jae Jeong, Kang, Kyung Ho, Lee, Hyun Kyung, Lee, Sung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609518/
https://www.ncbi.nlm.nih.gov/pubmed/30841020
http://dx.doi.org/10.4046/trd.2018.0019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609518/
https://www.ncbi.nlm.nih.gov/pubmed/30841020
http://dx.doi.org/10.4046/trd.2018.0019

Ejemplares similares